News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcobra (ADHD) Strengthens Management Team With Addition Of Industry Veteran David C. Baker As Chief Commercial Officer



1/13/2014 9:35:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Sustained-Release Metadoxine), to treat cognitive dysfunction, announced today that it has appointed David C. Baker as Chief Commercial Officer. Mr. Baker will be responsible for all pre-commercial activity for MG01CI and will lead the effort to establish brand awareness for the product in the medical community. He will also evaluate new opportunities for MG01CI, and other molecules in Alcobra's pipeline and will support general investor and public relations at the company.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Alcobra
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES